B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016

  • ID: 3928014
  • Report
  • 36 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Axxam SpA
  • Boehringer Ingelheim GmbH
  • Dompe Farmaceutici S.p.A.
  • Grunenthal GmbH
  • MORE
B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016

Summary

‘B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016’, provides in depth analysis on B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) targeted pipeline therapeutics.

The report provides comprehensive information on the B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
- Certain sections in the report may be removed or altered based on the availability and relevance of data.
- Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for B1 Bradykinin Receptor (BK1 Receptor or BDKRB1)
- The report reviews B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for B1 Bradykinin Receptor (BK1 Receptor or BDKRB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Axxam SpA
  • Boehringer Ingelheim GmbH
  • Dompe Farmaceutici S.p.A.
  • Grunenthal GmbH
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) Overview

Therapeutics Development

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Products under Development by Stage of Development

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Products under Development by Therapy Area

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Products under Development by Indication

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Products Glance

Early Stage Products

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Products under Development by Companies

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Products under Development by Universities/Institutes

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Companies Involved in Therapeutics Development

Axxam SpA

Boehringer Ingelheim GmbH

Dompe Farmaceutici S.p.A.

Grunenthal GmbH

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Drug Profiles

BI-113823 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize BDKRB1 for Pain and Ophthalmic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize BKB1R for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize Bradykinin B1 Receptor for Respiratory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Dormant Projects

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Discontinued Products

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Featured News & Press Releases

May 05, 2014: Possible Treatment for Kidney Disease in Lupus Studied at UH

Feb 07, 2014: Researchers Exploring Treatment For Lupus-Based Kidney Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Axxam SpA, H2 2016

Pipeline by Boehringer Ingelheim GmbH, H2 2016

Pipeline by Dompe Farmaceutici S.p.A., H2 2016

Pipeline by Grunenthal GmbH, H2 2016

Dormant Projects, H2 2016

Discontinued Products, H2 2016 31List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Axxam SpA
  • Boehringer Ingelheim GmbH
  • Dompe Farmaceutici S.p.A.
  • Grunenthal GmbH
  • MORE
B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) – Pipeline Review, H2 2016, outlays comprehensive information on the B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) Bradykinin receptor B1 is a G-protein coupled receptor encoded by the BDKRB1 gene. Its ligand is bradykinin generated in pathophysiologic conditions such as inflammation, trauma, burns, shock, and allergy. The B1 receptor is one of the G protein-coupled receptors that has found which bind bradykinin and mediate responses to these pathophysiologic conditions. The molecules developed by Companies in Preclinical and Discovery stages are 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Axxam SpA
Boehringer Ingelheim GmbH
Dompe Farmaceutici S.p.A.
Grunenthal GmbH
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll